NRCNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31
NRC HEALTH
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$20.47+0.32 (+1.59%)
Close on Oct 19, 2026
- Market cap
- $450.52M
- P/E (TTM)
- 0.4
- Dividend yield
- 2.54%
NRC HEALTH revenue by segment
By business segment
By product or service
By region
| Revenue | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $143.06M | $148.58M | $150.78M | $144.99M | $130.31M | $124.37M | $115.45M | $112.89M | $104.45M | $97.10M | 100.0% | -3.7% |
| Canada | $0 | $0 | $793.00K | $2.97M | $2.97M | $3.61M | $4.24M | $4.67M | $4.94M | $5.25M | 0.0% | – |
From the segment and revenue-disaggregation notes of Nrc Health's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.